Sequential Treatment Initiation with Timothy Grass and Ragweed Sublingual Immunotherapy Tablets Followed by Simultaneous Treatment Is Well Tolerated

Journal of Allergy and Clinical Immunology: In Practice

Volumn 4, Issue 2, 2016, Pages 301-309.e2

  Maloney, Jennifer ^a   Berman, Gary ^b   Gagnon, Remi ^c   Bernstein, David I ^d   Nelson, Harold S ^e   Kleine Tebbe, Jörg ^f   Kaur, Amarjot ^a   Li, Qing ^a   Nolte, Hendrik ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Clinical Research Institute   (United States)

^c Clinique Spécialisée en Allergie de la Capitale   (Canada)

^d UNIVERSITY OF CINCINNATI   (United States)

^e DEPARTMENT OF MEDICINE   (United States)

^f Allergy and Asthma Center Westend   (Germany)

Author keywords

Allergic rhinitis; Dual; Grass; Immunotherapy; Immunotherapy tablet; Ragweed; Safety; Simultaneous; Sublingual

Indexed keywords

GRASS POLLEN EXTRACT; RAGWEED POLLEN EXTRACT; ALLERGEN; PLANT ANTIGEN; TABLET;

ADULT; ADVERSE OUTCOME; AGED; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ARTICLE; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG SENSITIZATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR PRURITUS; EVENING DOSAGE; FEMALE; GLOSSODYNIA; HUMAN; HYPESTHESIA; INCIDENCE; LIP DISEASE; LIP EDEMA; LIP SWELLING; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MORNING DOSAGE; MOUTH EDEMA; MOUTH ULCER; MULTICENTER STUDY; NORTH AMERICAN; ORAL HYPESTHESIA; ORAL PARESTHESIA; ORAL PRURITUS; PALATAL EDEMA; PALATE DISEASE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHARYNGEAL EDEMA; PHARYNX DISEASE; PHASE 4 CLINICAL TRIAL; RECURRENT DISEASE; STOMATITIS; SUBLINGUAL IMMUNOTHERAPY; THROAT IRRITATION; TONGUE EDEMA; TONGUE SWELLING; TONGUE ULCER; TREATMENT DURATION; CANADA; CLINICAL TRIAL; COMBINATION DRUG THERAPY; IMMUNOLOGY; MIDDLE AGED; PHLEUM PRATENSE; PROCEDURES; RAGWEED; RHINITIS, ALLERGIC, SEASONAL; TABLET; UNITED STATES;

ADULT; ALLERGENS; AMBROSIA; ANTIGENS, PLANT; CANADA; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PHLEUM; RHINITIS, ALLERGIC, SEASONAL; SUBLINGUAL IMMUNOTHERAPY; TABLETS; UNITED STATES;

EID: 84960360846     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2015.11.004     Document Type: Article

References (13)

1. Salo P.M., Calatroni A., Gergen P.J., Hoppin J.A., Sever M.L., Jaramillo R., et al. Allergy-related outcomes in relation to serum IgE: results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol 2011, 127:1226-1235. e7.
2. Chan-Yeung M., Anthonisen N.R., Becklake M.R., Bowie D., Sonia Buist A., Dimich-Ward H., et al. Geographical variations in the prevalence of atopic sensitization in six study sites across Canada. Allergy 2010, 65:1404-1413.
3. Nelson H.S., Nolte H., Creticos P., Maloney J., Wu J., Bernstein D.I. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011, 127:72-80.e2.
4. Nolte H., Hebert J., Berman G., Gawchik S., White M., Kaur A., et al. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults. Ann Allergy Asthma Immunol 2013, 110:450-456. e4.
5. Ragwitek (short ragweed pollen allergen extract tablet for sublingual use). Full Prescribing Information 2014, Merck & Co., Inc., Kenilworth, NJ.
6. Grastek (timothy grass pollen allergen extract tablet for sublingual use). Full Prescribing Information 2014, Merck & Co., Inc., Kenilworth, NJ.
7. Maloney J., Bernstein D.I., Nelson H., Creticos P., Hebert J., Noonan M., et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol 2014, 112:146-153. e2.
8. Creticos P.S., Maloney J., Bernstein D.I., Casale T., Kaur A., Fisher R., et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol 2013, 131:1342-1349. e6.
9. Passalacqua G., Baena-Cagnani C.E., Bousquet J., Canonica G.W., Casale T.B., Cox L., et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol 2013, 132:93-98.
10. Wernicke J.F., Faries D., Milton D., Weyrauch K. Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods. Drug Saf 2005, 28:1057-1063.
11. Van Dyken A.M., Smith P.K., Fox T.L. Clinical case of anaphylaxis with sublingual immunotherapy: house dust mite allergen. J Allergy Clin Immunol Pract 2014, 2:485-486.
12. Agostinis F., Foglia C., Landi M., Cottini M., Lombardi C., Canonica G.W., et al. The safety of sublingual immunotherapy with one or multiple pollen allergens in children. Allergy 2008, 63:1637-1639.
13. Amar S.M., Harbeck R.J., Sills M., Silveira L.J., O'Brien H., Nelson H.S. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol 2009, 124:150-156. e1-5.